Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.51 |
| ▸ | KRAS | P01116 | 4/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | ELANE | P08246 | 4/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | TFPI | P10646 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29884109 | 0.97 | KRAS (0.49) | PLGKRASFLT1HDAC4ELANE | |
| SCHEMBL29773704 | 0.97 | KRAS (0.49) | PLGKRASFLT1HDAC4ELANE | |
| SCHEMBL29773696 | 0.97 | KRAS (0.49) | PLGKRASFLT1HDAC4ELANE | |
| SCHEMBL29390495 | 0.97 | KRAS (0.49) | PLGKRASFLT1HDAC4ELANE | |
| SCHEMBL12131181 | 0.96 | ELANE (0.51) | PLGKRASFLT1ELANETFPI | |
| SCHEMBL29773738 | 0.94 | PLG (0.52) | PLGKRASFLT1HDAC4ELANE | |
| SCHEMBL29390178 | 0.93 | PLG (0.51) | PLGKRASFLT1HDAC4ELANE | |
| Bacillomycin D(C14) SCHEMBL29777427 | 0.92 | SLC6A3 (0.52) | PLGKRASFLT1HDAC4ELANE | |
| SCHEMBL29884584 | 0.92 | KRAS (0.47) | PLGKRASFLT1HDAC4ELANE | |
| SCHEMBL30928172 | 0.92 | PLG (0.49) | PLGKRASHDAC4ELANEHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270567-A1 | GENERATION OF ACYL AMINO ACIDS | MODULAR GENETICS INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-12123004-B2 | Generation of acyl amino acids | MODULAR GENETICS, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-12031167-B2 | Generation of acyl amino acids | MODULAR GENETICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220259626-A1 | GENERATION OF ACYL AMINO ACIDS | MODULAR GENETICS, INC. | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259626-A1 | GENERATION OF ACYL AMINO ACIDS | FADS1, FADS2, FAR1 | PLG 1385/4885KRAS 973/4885FLT1 1562/4885 |
| US-12031167-B2 | Generation of acyl amino acids | FADS1, FADS2, FAR1 | PLG 1385/4885KRAS 973/4885FLT1 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.